Artiva Biotherapeutics, Inc. Common Stock
ARTVArtiva Biotherapeutics, Inc. is a biotechnology company focused on developing off-the-shelf natural killer (NK) cell therapies for cancer treatment. The company aims to leverage its proprietary platforms to create innovative immunotherapies that enhance the body's immune response against tumors. Founded with a focus on advancing cell therapy technologies, Artiva is dedicated to addressing unmet needs in oncology.
Company News
Artiva Biotherapeutics announced the appointment of Diego Miralles, M.D., as President and Head of Research and Development. Miralles brings over 20 years of biotech leadership experience and previously served on Artiva's Board. The appointment comes as Artiva prepares for Phase 3 registrational trials of its lead program AlloNK in refractory rhe...
DelveInsight's 2026 report reveals a robust rheumatoid arthritis pipeline with 75+ active players developing 80+ drugs across various clinical stages. The report highlights emerging therapies targeting novel pathways beyond traditional TNF inhibition, including JAK inhibitors, BTK inhibitors, and cell-based immunotherapies. Recent developments in...
Artiva Biotherapeutics announced that its management will participate in a panel and fireside chat at the 25th Annual Needham Virtual Healthcare Conference on April 15, 2026. The clinical-stage biotech company is developing cell therapies for autoimmune diseases and cancers, with its lead program AlloNK currently in three ongoing clinical trials ...
Artiva Biotherapeutics appointed Thad Huston as Chief Financial Officer, bringing over 30 years of global leadership experience in pharmaceuticals, biotechnology, and medical devices. Huston received an inducement grant of 220,000 restricted stock units vesting over four years. The appointment comes as Artiva prepares to receive FDA feedback on i...
Artiva Biotherapeutics reported treating over 100 patients with AlloNK across autoimmune and oncology indications, receiving FDA Fast Track Designation for refractory rheumatoid arthritis treatment. The company expects initial clinical response data in first half of 2026 and has $123 million cash runway into Q2 2027.
